JB Chemicals to strike Rs 628 crore deal with Sanzyme for probiotic, reproductive brands
Mumbai: J.B. Chemicals & Pharmaceuticals Limited (JBCPL) has recently announced that it will acquire brands for the India market from Sanzyme Private Limited. The transaction is valued at INR ~ 628* crore and is expected to be completed in the next two weeks subject to customary closing formalities.
The acquisition will mark JBCPL's entry into the fast-growing probiotics, therapeutic nutraceuticals and reproductive health market with attractive set of brands.
JBCPL will be amongst the top five probiotics players in the country, in a segment which is growing at around 12 -14%. This category creates synergies with its strong prescriber base in gastroenterology and nephrology segments.
Leading brands like Sporlac, Lobun, Oxalo, Pubergen, Nano-leo and Gynogen will now be part of the JBCPL franchise, the company said in its recent release.
o3 Capital was the exclusive advisor to Sanzyme for the transaction.
"We are glad to announce our first acquisition which expands our presence into new Therapeutic areas and also increases the addressable opportunity in the India Pharma market. This is in line with our stated objective of building big brands through category leaders. Sanzyme has been a pioneer in the probiotics segment and we wish to build further on this legacy" mentioned Mr. Nikhil Chopra, CEO & Whole-time Director, J.B. Chemicals & Pharmaceuticals Limited. He further added "This acquisition also reinforces our strategic intent to evaluate opportunities to supplement our growth ambition in India. Overall, our objective is to deploy capital judiciously to enhance value for all stakeholders."
Sanzyme, ranked amongst the top five probiotics players in the country, is engaged in the manufacture, distribution and marketing of specialty probiotics formulations, infertility management products and nutraceuticals products. It operates in the gastroenterology, nephrology, urology and gynecology therapy areas with leading brands such as Sporlac, Lobun, and Gynogen. As per IQVIA MAT Dec 21 data, the revenue for the combined brands was INR 160 crores.
